Semaglutide belongs to a class of long-acting incretin mimetics, and its weight-loss mechanism centers on two key actions: 1. Central appetite suppression: It acts on the brain's feeding centers to reduce hunger at its source, naturally diminishing the desire to overeat. 2. Delayed gastric emptying: It prolongs the time food remains in the stomach, fostering a sustained sense of satiety that allows you to feel full after consuming only a small amount of food.
Through the synergistic effect of these dual actions, the medication helps reduce daily caloric intake, thereby facilitating weight loss. The efficacy of Semaglutide injections for weight loss varies from person to person. Clinical data indicates that after 68 weeks of continuous use, users experienced an average weight reduction of 17% and an average waist circumference reduction of 15.8 cm; furthermore, the greater the user's baseline weight, the more pronounced the magnitude of weight loss. Approximately 10% of users experience primary non-response, showing no significant weight loss following treatment.
Clinical data also reveals that more than half of users experience weight regain after discontinuing the medication. However, the primary cause of this rebound is not drug dependence, but rather a reversion to unhealthy lifestyle habits-specifically binge eating, a diet high in fats and sugars, and a sedentary lifestyle. The only way to prevent weight regain is to consistently adhere to scientifically sound lifestyle interventions-both during the course of treatment and after discontinuation. If one maintains a healthy diet and engages in regular exercise after stopping the medication, weight will not only remain stable but may even continue to decrease gradually. Should weight regain occur within six months of discontinuation, the medication may be resumed under a physician's guidance; if more than six months have elapsed, a return to the hospital for a comprehensive risk assessment is required before resuming treatment.